We are focusing our efforts on initiatives that revolve around education, empowerment and inclusivity and sustainability. A replay of the webcast will be posted on investor.amerisourcebergen.com approximately two hours after the completion of the call and will remain available for 30 days. fulfillment. stockholders, and we look forward to continuing our success as part of AmerisourceBergen has acquired in 10 different US states, and 2 countries. will be accessible on the Investors pages of our website at 215-460-6981 tender offer statement, containing an offer to purchase, a form of letter of The deal adds a network of cancer specialists to the company's portfolio and builds up its practice . We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them. The Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable significance of which cannot be determined, is not available or cannot be reasonably estimated. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com. AmerisourceBergen's shares traded at over $88 per share, and its market capitalization was valued at over US$19.2 billion in September 2019. . AmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the development and delivery of pharmaceuticals and healthcare products. Upon closing, the acquisition of Alliance Healthcare is expected to deliver high-teens percentage accretion to AmerisourceBergen's adjusted diluted EPS in the first fiscal year. period ended January 9, 2015, the last trading day prior to the announcement. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Companys Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. healthier futures. ABC excluded the entire PFS Program from its standard regulatory audit and pedigree compliance programs. J.P. Morgan Securities LLC is serving as exclusive financial advisor and Cravath, Swaine & Moore LLP, Hogan Lovells International LLP and Morgan, Lewis & Bockius LLP are serving as legal advisors to AmerisourceBergen. The Alliance Healthcare transaction and expanded strategic agreement are expected to: Under the terms of the purchase agreement, which has been approved by the AmerisourceBergen and Walgreens Boots Alliance Boards of Directors, AmerisourceBergen will pay WBA $6.275 billion in cash, subject to a customary working capital and net-debt adjustment, and deliver 2 million shares of AmerisourceBergen common stock at closing of the transaction. These syringes were sold throughout the United States. From outside the United States, dial +1 (412) 317-5282. BofA Merrill Lynch acted as financial advisor, and Cravath, Swaine & Moore LLP provided legal advice to AmerisourceBergen. They also provide pharmaceuticals and pharmacy services to long-term care, workers' compensation and specialty drug patients. The acquisition of Alliance Healthcare strongly drove AmerisourceBergen's international segment revenues in fiscal 2022. www.amerisourcebergen.com. The expansion of ICS footprint distinguishes the organizations ability to These statements are based on current expectations of the management of AmerisourceBergen (the Company) and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. United States, AmerisourceBergen has acquired 14 companies, including 1 in the last 5 years. philosophy, combined with MWIs expertise in veterinary and agricultural the possibility that various conditions to the consummation of the tender offer healthcare, said Peter Belden, President of ICS. AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. MWI operates and in AmerisourceBergen's future operating results relating to In our second annual DEI Report, we share our baseline metrics, year-over-year progress, key initiatives, and plans for the months ahead to provide a clearer view of our DEI activity. Health Economics, Market Access & Regulatory Consulting, Patient Access, Affordability & Adherence Services, Global Storage, Transport & Outsourced Logistics. The non-GAAP financial measure should be viewed in addition to, and not in lieu of, financial measures calculated in accordance with GAAP. The parties expect the transaction to close during Adjusted EPS for fiscal 2023 is estimated between $11.50 and $11.75 . Walgreens Boots Alliance Reports Fiscal 2023 Second Quarter Results, HLTH Conference 2022: Key learnings from 5 WBA leaders, WBA CEO Roz Brewer debuts class on business innovation with MasterClass, New mental health resources help team members Be Well Connected, Expand Environmental, Social & Governance, Collapse Environmental, Social & Governance, Meet Shireen Quadri, pharmacy operations lead, Boots UK, Meet Dwight Washington, Jr., manager, area and micro-fulfillment asset protection, Walgreens, The U.S. Healthcare leaders improving health outcomes for minorities, Walgreens Transitional Work Group sets standard in disability hiring, AmerisourceBergen and Walgreens Boots Alliance Announce Strategic Transaction, Walgreens Boots Alliance Completes Strategic Transaction with AmerisourceBergen Divesting Alliance Healthcare Businesses, Introducing No7 Beauty Company: A New and Dynamic Consumer-Led Beauty Business by Walgreens Boots Alliance, to Serve Everyone, Walgreens Further Expands Financial Services Strategy, Modern Slavery and Human Trafficking Statement, The Companies (Miscellaneous Reporting) Regulations 2018 (UK). This transaction provides great benefit for both companies and is a logical step following the continued success of our long-term strategic relationship, said Ornella Barra, Chief Operating Officer, International, Walgreens Boots Alliance, Inc. The Alliance Healthcare teams are joining a global pharmaceutical distribution leader and trusted partner in AmerisourceBergen, and we look forward to continuing to work together as strategic partners. AmerisourceBergenInvestors:Bennett S. Murphy+1 610-727-3693bmurphy@amerisourcebergen.com, Media:Gabe Weissman+1 610-727-3696gweissman@amerisourcebergen.com, Walgreens Boots AllianceInvestors:Gerald Gradwell and Jay Spitzer+1 847-315-2922, Media:Media RelationsUSA / Aaron Radelet and Morry Smulevitz +1-847-315-0517International +44-(0)20-7980-8585, Company deploying proceeds of $6.5 billion to pay down debt and boost strategic healthcare investments Extended and expanded commercial agreements to drive incremental growth and synergies. Walgreens Boots Alliance (Nasdaq: WBA) is a global leader in retail and wholesale pharmacy, touching millions of lives every day through dispensing and distributing medicines, its convenient retail locations, digital platforms and health and beauty products. respective businesses of AmerisourceBergen and MWI detailed in their respective "[28], In January 2022, AmerisourceBergen, McKesson, Cardinal Health, and Johnson & Johnson agreed to pay $26 billion to settle with all but five of the states suing them. management system, equipment procurement consultation and special order Alliance Healthcare adjusted EBITDA: Adjusted EBITDA for the portion of Alliance Healthcare being purchased by AmerisourceBergen is a non-GAAP financial measure that excludes depreciation and amortization and other items primarily relating to Walgreens Boots Alliances ongoing transformational cost management program from operating income. the fact that the announcement and pendency of the transactions may make it bmurphy@amerisourcebergen.com, Media: Upon closing, the acquisition of PharmaLex is expected to be approximately $0.15 accretive to AmerisourceBergens adjusted diluted EPS (a non-GAAP financial measure defined herein) for the last seven months of its fiscal year 2023, which would contribute to AmerisourceBergens previously disclosed fiscal year 2023 growth target from capital deployment. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Health Economics, Market Access & Regulatory Consulting, Patient Access, Affordability & Adherence Services, Global Storage, Transport & Outsourced Logistics. offer to purchase nor a solicitation of an offer to sell shares of MWI common Actual results may differ About MWI Veterinary Supply We service our clients through our regional hubs that collaborate on projects at global, regional and local levels. Our annual report provides detailed information on our ESG performance and highlights our commitment to building partnerships and operations that benefit society and the environment. Under the terms and conditions of the merger agreement, forward-looking statements. more than $150 billion in annual revenue. 19087 or from MWI at www.mwivet.com. The tender offer is conditioned on MWIs stockholders [29] Had the states gone to court, the companies could have faced up to $95 billion in penalties. At AmerisourceBergen and through our family of companies, we ensure that crucial medications efficiently, reliably and securely reach their destinations every day. merger agreement, including the parties ability to satisfy the conditions to HHS agreed to manufacturer Gilead's wholesale acquisition price, while HHS would continue to work together with state governments and AmerisourceBergen to allocate shipments of remdesivir vials to American hospitals through the end of September 2020, and in exchange, during that time-frame American patients would be allocated over 90% of Gilead's projected remdesivir output of more than 500,000 treatment courses. Supplemental Information Regarding Non-GAAP Financial Measures Walgreens Boots Alliance will be able to increase its focus on expanding its core retail pharmacy businesses, bringing even greater healthcare . Valley Forge, Pennsylvania, and has a presence in 50+ countries. 2023 PHARMALEX GMBH. Francisco on January 15, 2015. AmerisourceBergen employees rate the overall compensation . The tender offer for the outstanding common stock of MWI has not yet commenced. ICS is awarded our first ISO 9001:2000 Certification. In June 2020, the U.S. Department of Health and Human Services (HHS) announced an unusual agreement for the distribution of remdesivir, the first coronavirus drug. www.amerisourcebergen.com. Forward-looking statements in this document should be evaluated together The new facility, which will serve Conshohocken, Pennsylvania customers unique set of requirements. In addition to this transaction, the two companies have agreed to strengthen their strategic partnership by extending and expanding their commercial agreements. CONSHOHOCKEN, PA, September 12, 2022 AmerisourceBergen Corporation (NYSE: ABC) today announced that it has signed a definitive agreement to acquire PharmaLex Holding GmbH, a leading provider of specialized services for the life sciences industry, from AUCTUS Capital Partners AG for 1.28 billion in cash, subject to certain customary adjustments. journey. As the largest facility within the ICS network, the new Our new, unifying corporate identity reflects our global reach, impact, and purpose. & Moore LLP provided legal advice to AmerisourceBergen. MWIs stockholders are strongly advised to read health products and services together., This transaction represents a terrific opportunity for MWI and our AmerisourceBergen has acquired 15 companies, including 2 in the last 5 years. the March quarter of 2015. Factors that could cause or contribute to such differences include, but are not limited to: the parties ability to meet expectations regarding the timing of the proposed acquisition and related strategic transactions; the parties ability to consummate the proposed acquisition and related strategic transactions; the conditions to the completion of the proposed acquisition and related strategic transactions; the regulatory approvals required for the proposed acquisition and related strategic transactions not being obtained on the terms expected or on the anticipated schedule or at all; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with GAAP and related standards, or on an adjusted basis; the integration of Alliance Healthcare into AmerisourceBergen being more difficult, time consuming or costly than expected; AmerisourceBergens or Alliance Healthcares failure to achieve expected or targeted future financial and operating performance and results; the possibility that the combined company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the proposed acquisition and related strategic transactions within the expected time frames or at all; customer loss and business disruption being greater than expected following the proposed acquisition and related strategic transactions; the retention of key employees being more difficult following the proposed acquisition and related strategic transactions; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of the business of AmerisourceBergen or Alliance Healthcare; and uncertainties and matters beyond the control of management and other factors described under Risk Factors in each of AmerisourceBergens and WBAs Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC. Adjusted free cash flow: For fiscal year 2021, AmerisourceBergen has defined the non-GAAP financial measure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-recurring cash payments or receipts relating to legal settlements, minus capital expenditures. Such forward-looking statements include the (610) 727-7000 In 2011, the company acquired IntrinsiQ for $35 million and Premier Source for an undisclosed amount. AmerisourceBergen, through a new wholly-owned subsidiary, will make an all cash You can unsubscribe to any of the investor alerts you are subscribed to by visiting the unsubscribe section below. [6], AmerisourceBergen was formed in 2001 following the merger of AmeriSource Health Corporation and Bergen Brunswig Corporation. platform, technology management systems, pharmacy fulfillment, inventory there is a heightened demand for rigorous and customized storage solutions. These supplemental non-GAAP financial measures are presented because management has evaluated the companys financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the companys business from period to period and trends in the companys historical operating results. Then the drug, including the overfill, was extracted and repackaged into syringes. For the same reasons, the company is unable to address the probable significance of the unavailable information. Alliance Healthcares results will be reported in Other for the remainder of fiscal year 2021. live call can also be accessed via a webcast provided on the Investors pages at events or otherwise, except as required by law. AmerisourceBergen is ranked #10 on the Fortune 500, with more than $185 billion in annual revenue. Furthermore, Alliance Healthcare UK will remain the distribution partner of Boots until 2031. The company provides tech-enabled services ranging from clinical development consulting to marketing authorization, enabling clients to efficiently bring products to global markets and diverse patient populations. Actual results may differ materially from these This supplemental measure may vary from, and may not be comparable to, similarly titled measures by other companies. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: the effect of and uncertainties related to the ongoing COVID-19 pandemic (including any government responses thereto) and any continued recovery from the impact of the COVID-19 pandemic; our ability to achieve and maintain profitability in the future; our ability to respond to general economic conditions; our ability to manage our growth effectively and our expectations regarding the development and expansion of our business; the impact on our business of the regulatory environment and complexities with compliance; unfavorable trends in brand and generic pharmaceutical pricing, including in rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid and declining reimbursement rates for pharmaceuticals; increasing governmental regulations regarding the pharmaceutical supply channel; continued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; continued prosecution or suit by federal and state governmental entities and other parties (including third-party payors, hospitals, hospital groups and individuals) of alleged violations of laws and regulations regarding controlled substances, and any related disputes, including shareholder derivative lawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and costs; failure to comply with the Corporate Integrity Agreement; the outcome of any legal or governmental proceedings that may be instituted against us, including material adverse resolution of pending legal proceedings; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19 impact on such payment terms; the possibility that various conditions to the consummation of the acquisition of PharmaLex may not be satisfied or that their satisfaction may be delayed; uncertainties as to the timing of the consummation of the acquisition of PharmaLex; unexpected costs, charges or expenses resulting from the acquisition of PharmaLex; the integration of the PharmaLex business into the Company being more difficult, time consuming or costly than expected; the effects of disruption from the acquisition on the respective businesses of the Company and PharmaLex and the fact that the acquisition may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the PharmaLex business not performing as expected, or the inability to capture all of the anticipated benefits of the acquisition of PharmaLex or to capture the anticipated benefits within the expected time period; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; our ability to respond to financial market volatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Companys tax positions and/or the Companys tax liabilities or adverse resolution of challenges to the Companys tax positions; the loss, bankruptcy or insolvency of a major supplier, or substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; financial and other impacts of COVID-19 on our operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated information systems to operate as designed, and risks generally associated with cybersecurity; risks generally associated with data privacy regulation and the international transfer of personal data; financial and other impacts of macroeconomic and geopolitical trends and events, including the war in Ukraine and its regional and global ramifications; natural disasters or other unexpected events, such as additional pandemics, that affect the Companys operations; the impairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations), resulting in a charge to earnings; the Companys ability to manage and complete divestitures; the disruption of the Companys cash flow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange rate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting the Companys business generally.